Plexus Corp. (NASDAQ: PLXS – Get a rating) insider Scott Theune sold 1,678 shares of the company in a trade dated Thursday, May 26. The stock was sold at an average price of $83.04, for a total value of $139,341.12. As a result of the transaction, the insider now owns 7,500 shares of the company, valued at approximately $622,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, available at this hyperlink.
Plexus stock traded down $0.14 in midday trading on Tuesday, hitting $84.80. The stock had a trading volume of 109,544 shares, compared to an average volume of 135,758. The company’s fifty-day simple moving average is $81.22 and its 200-day simple moving average is 84. $.81. Plexus Corp. has a 1-year low of $72.88 and a 1-year high of $100.39. The stock has a market capitalization of $2.35 billion, a P/E ratio of 21.86 and a beta of 1.10. The company has a debt ratio of 0.18, a quick ratio of 0.64 and a current ratio of 1.47.
Plexus (NASDAQ: PLXS – Get a rating) last announced its results on Wednesday, April 27. The technology company reported earnings per share (EPS) of $0.95 for the quarter, beating consensus analyst estimates of $0.83 by $0.12. Plexus had a return on equity of 11.05% and a net margin of 3.31%. The company posted revenue of $888.70 million for the quarter, versus analyst estimates of $839.76 million. In the same quarter last year, the company achieved EPS of $1.49. Plexus revenue for the quarter increased 0.9% compared to the same quarter last year. On average, sell-side analysts expect Plexus Corp. will post earnings per share of 4.1 for the current fiscal year.
A number of equity analysts have published reports on PLXS shares. TheStreet upgraded Plexus from a ‘b’ rating to a ‘c+’ rating in a Thursday, February 24 report. StockNews.com launched a coverage on Plexus in a research report on Thursday, March 31. They have placed a “holding” rating on the stock. To finish, Zacks Investment Research downgraded Plexus from a “strong sell” rating to a “hold” rating and set a price target of $88.00 on the stock in a Wednesday, March 30 research report. Three equity research analysts gave the stock a hold rating and four gave the stock a buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $98.12.
A number of institutional investors have recently changed their positions in PLXS. Morgan Stanley increased its position in Plexus by 61.2% in the second quarter. Morgan Stanley now owns 136,070 shares of the technology company valued at $12,437,000 after buying an additional 51,646 shares in the last quarter. Allianz Asset Management GmbH increased its position in Plexus shares by 137.0% during the third quarter. Allianz Asset Management GmbH now owns 6,549 shares of the technology company worth $586,000 after buying 3,786 additional shares in the last quarter. Martingale Asset Management LP increased its position in Plexus shares by 63.1% during the third quarter. Martingale Asset Management LP now owns 35,428 shares of the technology company worth $3,169,000 after purchasing an additional 13,701 shares in the last quarter. GSA Capital Partners LLP increased its position in Plexus shares by 40.4% during the third quarter. GSA Capital Partners LLP now owns 5,135 shares of the technology company worth $459,000 after buying 1,477 additional shares in the last quarter. Finally, FCA Corp TX increased its position in Plexus shares by 0.9% during the third quarter. FCA Corp TX now owns 14,686 shares of the technology company worth $1,313,000 after buying 126 more shares in the last quarter. 94.92% of the shares are currently held by institutional investors and hedge funds.
Plexus Company Profile (Get a rating)
Plexus Corp., together with its subsidiaries, provides electronics manufacturing services in the Americas, Europe, the Middle East, Africa and Asia-Pacific. It offers design and development, supply chain, new product introduction and manufacturing solutions, and aftermarket services to companies in the healthcare/life sciences, industry/commerce, aerospace/defense and communications.
Get news and reviews for Plexus Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Plexus and related companies with MarketBeat.com’s free daily email newsletter.